Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

Melchior Linea,Hirschmann Astrid,Hofman Paul,Bontoux Christophe,Concha Angel,Mrabet-Dahbi Salima,Vannuffel Pascal,Watkin Emmanuel,Putzová Martina,Scarpino Stefania,Cayre Anne,Martin Paloma,Stoehr Robert,Hartmann Arndt

DOI: https://doi.org/10.1007/s00428-024-03778-9

2024-03-17

Virchows Archiv

Abstract:The current study assessed the performance of the fully automated RT-PCR-based IdyllaTM GeneFusion Assay, which simultaneously covers the advanced non-small cell lung carcinoma (aNSCLC) actionable ALK , ROS1 , RET , and MET exon 14 rearrangements, in a routine clinical setting involving 12 European clinical centers. The IdyllaTM GeneFusion Assay detects fusions using fusion-specific as well as expression imbalance detection, the latter enabling detection of uncommon fusions not covered by fusion-specific assays. In total, 326 archival aNSCLC formalin-fixed paraffin-embedded (FFPE) samples were included of which 44% were resected specimen, 46% tissue biopsies, and 9% cytological specimen. With a total of 179 biomarker-positive cases (i.e., 85 ALK , 33 ROS1 , 20 RET fusions and 41 MET exon 14 skipping), this is one of the largest fusion-positive datasets ever tested. The results of the IdyllaTM GeneFusion Assay were compared with earlier results of routine reference technologies including fluorescence in situ hybridization, immunohistochemistry, reverse-transcription polymerase chain reaction, and next-generation sequencing, establishing a high sensitivity/specificity of 96.1%/99.6% for ALK , 96.7%/99.0% for ROS1 , 100%/99.3% for RET fusion, and 92.5%/99.6% for MET exon 14 skipping, and a low failure rate (0.9%). The IdyllaTM GeneFusion Assay was found to be a reliable, sensitive, and specific tool for routine detection of ALK , ROS1 , RET fusions and MET exon 14 skipping. Given its short turnaround time of about 3 h, it is a time-efficient upfront screening tool in FFPE samples, supporting rapid clinical decision making. Moreover, expression-imbalance-based detection of potentially novel fusions may be easily verified with other routine technologies without delaying treatment initiation.

pathology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the performance of Idylla™ GeneFusion Assay in the actual clinical environment. This is a fully - automated RNA - based real - time PCR detection method for simultaneously detecting ALK, ROS1, RET fusions and MET exon 14 skipping in non - small - cell lung cancer (NSCLC). Specifically, the study aims to: 1. **Evaluate detection accuracy**: By comparing with the results of conventional reference techniques (such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), reverse transcription - polymerase chain reaction (RT - PCR) and next - generation sequencing (NGS)), evaluate the sensitivity and specificity of Idylla™ GeneFusion Assay in detecting these gene rearrangements. 2. **Verify detection reliability**: Test 326 archived advanced NSCLC (stage IV) formalin - fixed paraffin - embedded (FFPE) tissue samples in the real - clinical environment of 12 European clinical centers to verify the reliability and consistency of this detection method. 3. **Improve detection efficiency**: The study also explores the potential of Idylla™ GeneFusion Assay as a rapid screening tool, especially when dealing with limited FFPE materials, being able to provide results within 3 hours, thus supporting rapid clinical decision - making. 4. **Explore the value of expression imbalance detection**: In addition to the detection of specific fusions, Idylla™ GeneFusion Assay can also detect uncommon fusions by analyzing the expression imbalance of ALK, ROS1 and RET, which helps to improve the detection sensitivity, especially when detecting ALK and RET fusions. In conclusion, this study aims to verify the feasibility and advantages of Idylla™ GeneFusion Assay as a rapid, reliable and efficient detection tool for detecting fusions related to targeted therapy in NSCLC patients in the actual clinical environment.

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study

RET Fusion Detection Using IdyllaTM Gene Fusion Assay

Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer

A highly sensitive XNA-based RT-qPCR assay for the identification of ALK, RET, and ROS1 fusions in lung cancer

A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients

Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day

Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound‐guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non‐small‐cell lung carcinomas on the Biocartis IdyllaTM platform

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance

Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation

Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

Evaluation of the Idylla™ EGFR Mutation Test on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Comprehensive evaluation of the test for 5′‐/3′‐end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer

Development of a novel ALK rearrangement screening test for non-small cell lung cancers

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

RET Fusion Testing in Patients With NSCLC: The RETING Study

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Clinical evaluation of the effectiveness of fusion‐induced asymmetric transcription assay‐based reverse transcription droplet digital <scp>PCR</scp> for <scp> <i>ALK</i> </scp> detection in formalin‐fixed paraffin‐embedded samples from lung cancer